VRTX announcements Vertex Pharmaceuticals Incorporated announcements and dividends declared USA
Vertex Pharmaceuticals Incorporated Complete list of announcements declared & dividend announcements by Vertex Pharmaceuticals Incorporated VRTX
Vertex Pharmaceuticals Incorporated VRTX listed on USA and deals in Health Care Major PharmaceuticalsAnnouncements and dividends declared by Vertex Pharmaceuticals Incorporated VRTX
Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
Vertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals (NASDAQ:VRTX) is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug povetacicept, with a series of clinical readouts expected through 2027 as
Announcement as on 17 November 2026
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
Vertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease,
Announcement as on 16 November 2026
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead
Vertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the comp
Announcement as on 14 September 2026
Vertex Pharmaceuticals Q2 Earnings Call Highlights
Vertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to .3 billion, driven by continued growth in its cystic fibrosis franchise and risin
Announcement as on 03 August 2026
Vertex Pharmaceuticals Bets Billion on Crinetics to Build Endocrinology Powerhouse
Vertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for per share in cash, a transaction Vertex executives describe
Announcement as on 11 July 2026
Announcements by Vertex Pharmaceuticals Incorporated first page | Next page |
VRTX Vertex Pharmaceuticals Incorporated current price & indicator signals
Recent prices of VRTX Vertex Pharmaceuticals Incorporated are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 20 Fri Nov 2026 | 515.02 | 513.80 to 531.37 | -1.08% | 1.56 times |
| 19 Thu Nov 2026 | 520.66 | 517.82 to 537.79 | -2.94% | 1.04 times |
| 18 Wed Nov 2026 | 536.42 | 531.38 to 542.76 | 0.42% | 0.79 times |
| 17 Tue Nov 2026 | 534.20 | 529.00 to 538.56 | -0.67% | 1.33 times |
| 16 Mon Nov 2026 | 537.79 | 534.12 to 549.56 | -0.15% | 1.08 times |
| 13 Fri Nov 2026 | 538.60 | 536.12 to 543.73 | -0.74% | 0.67 times |
| 12 Thu Nov 2026 | 542.62 | 542.51 to 552.27 | -0.81% | 0.87 times |
| 11 Wed Nov 2026 | 547.03 | 535.46 to 548.67 | -0.16% | 0.95 times |
| 10 Tue Nov 2026 | 547.89 | 543.44 to 551.86 | -0.54% | 1.09 times |
| 09 Mon Nov 2026 | 550.87 | 538.48 to 555.99 | 0.69% | 1.07 times |
| 06 Fri Nov 2026 | 547.09 | 531.53 to 548.76 | 0.85% | 1.12 times |
| 05 Thu Nov 2026 | 542.50 | 540.02 to 557.85 | -1.19% | 2.19 times |
Videos related to: VRTX announcements Vertex Pharmaceuticals Incorporated announcements and dividends declared USA
Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra
Hindi Video What Is Needed To Succeed In Stock Markets
- USA Screeners
- USA Daily Screener
- USA Weekly Screener
- USA Monthly Screener
- Support & Resistance
- USA Shares Near Support
- USA Shares Near Resistance


